MedPath

Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

Phase 3
Completed
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
Drug: vancomycin+aztreonam
Registration Number
NCT03137173
Lead Sponsor
Basilea Pharmaceutica
Brief Summary

This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).

Detailed Description

This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients with ABSSSIs. Randomization was stratified by study site and type of ABSSSI (with major cutaneous abscess comprising ≤ 30% of the Intent-to-Treat \[ITT\] population).

Primary endpoint for FDA: Early clinical response based on the percent reduction in lesion size at 48-72 hours compared to baseline in patients who did not receive rescue therapy and were alive, in the ITT population.

Primary endpoint for EMA: Investigator-assessed clinical success at the test-of-cure (TOC) visit 15-22 days after randomization, in the co-primary ITT and Clinically Evaluable (CE) populations.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
679
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
vancomycin+aztreonamvancomycin+aztreonamPatients treated with vancomycin 1000 mg (or 15 mg/kg) q12h plus aztreonam 1000 mg q12h (both with dose adjustment for renal impairment).
ceftobiprole medocarilceftobiprole medocarilPatients treated with ceftobiprole medocaril 500 mg q8h (with dose adjustment for renal impairment).
Primary Outcome Measures
NameTimeMethod
Early Clinical Response48-72 hours after start of study drug treatment

Comparison of early clinical response, including ≥ 20% reduction from baseline in the primary lesion area (based on ruler measurements), survival for ≥ 72 hours and no rescue therapy in the ITT population

Secondary Outcome Measures
NameTimeMethod
Investigator-assessed Clinical Success in the Clinically Evaluable (CE) Population15-22 days after randomization

Comparison of investigator-assessed clinical success (based on resolution of baseline signs and symptoms of the primary infection) in the clinically evaluable (CE) population

Investigator-assessed Clinical Success in the ITT Population15-22 days after randomization

Comparison of investigator-assessed clinical success (based on resolution of baseline signs and symptoms of the primary infection) in the ITT population

Trial Locations

Locations (32)

Physician Alliance Research Center

🇺🇸

Anaheim, California, United States

Central Valley Research LLC

🇺🇸

Fresno, California, United States

L&C Professional Medical Research Institute

🇺🇸

Miami, Florida, United States

Mercury Street Medical Group

🇺🇸

Butte, Montana, United States

Gonzalez MD and Aswad MD Health Services

🇺🇸

Coral Gables, Florida, United States

"University Multiprofile Hospital for Active Treatment and Emergency Medicine ""N. I. Pirogov"", Clinic of Purulent-Septic Surgery-"N.I. Pirogov""

🇧🇬

Sofia, Bulgaria

South Jersey Infectious Disease

🇺🇸

Somers Point, New Jersey, United States

University of SzegednAlbert Szent-Gyorgyi Clinical Center

🇭🇺

Szeged, Hungary

Kaposi Mor Teaching Hospital

🇭🇺

Kaposvar, Hungary

CRU Hungary Ltd.

🇭🇺

Miskolc, Hungary

Csolnoky Ferenc Hospital

🇭🇺

Veszprem, Hungary

Dnipropetrovsk I.I. Mechnуkov Regional Clinical Hospital, Surgery Department #2

🇺🇦

Dnipro, Ukraine

Lviv Regional Clinical Hospital

🇺🇦

Lviv, Ukraine

Ivano-Frankivsk City Clinical Hospital Surgery 1

🇺🇦

Ivano-Frankivsk, Ukraine

Ivano-Frankivsk City Clinical Hospital General Surgery

🇺🇦

Ivano-Frankivsk, Ukraine

Kyiv City Clinical Hospital

🇺🇦

Kyiv, Ukraine

Public City Clinical Hospital of Emergency Medical Care

🇺🇦

Lviv, Ukraine

eStudySite - Las Vegas - PPDS

🇺🇸

Las Vegas, Nevada, United States

Excel Clinical Research

🇺🇸

Las Vegas, Nevada, United States

Omnibus Clinical Research

🇺🇸

La Palma, California, United States

Saint Joseph's Clinical Research

🇺🇸

Anaheim, California, United States

Marvel Clinical Research

🇺🇸

Huntington Beach, California, United States

eStudySite - Chula Vista - PPDS

🇺🇸

Chula Vista, California, United States

eStudySite - La Mesa - PPDS

🇺🇸

La Mesa, California, United States

Long Beach Clinical Trials

🇺🇸

Long Beach, California, United States

Central Valley Research, LLC

🇺🇸

Modesto, California, United States

University Multiprofile Hospital for Active Treatment

🇧🇬

Ruse, Bulgaria

Central City Clinical Hospital

🇺🇦

Uzhhorod, Ukraine

Vinnytsia M.I. Pyrohov Regional Clinical Hospital

🇺🇦

Vinnytsia, Ukraine

Central District Hospital

🇺🇦

Zhytomyr, Ukraine

Zaporizhia City Clinical Hospital of Urgent and Emergency Medical Care

🇺🇦

Zaporizhia, Ukraine

Alliance Research LLC

🇺🇸

Long Beach, California, United States

© Copyright 2025. All Rights Reserved by MedPath